Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.
Felipe BataliniDoga C GulhanVictor Y MaoAntuan V TranMadeline PolakNiya XiongNabihah TayobNadine M TungEric P WinerErica L MayerStian KnappskogPer Eystein LønningUrsula A MatulonisPanagiotis A KonstantinopoulosDavid B SolitHelen H WonHans Petter EikesdalPeter J ParkGerburg M WulfPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our analyses demonstrate that HRD can be detected reliably from panel-sequencing data that are obtained as part of routine clinical care, and that this approach can identify patients beyond those with germline BRCA1/2mut who might benefit from PARP inhibitors. Prospective clinical utility testing is warranted.